Objective: Human urotensin II (hUII) is an endocrine hormone that acts as a potent arterial vasoconstrictor in both in vitro and in vivo studies in animals. We examined, for the first time, the local and systemic hemodynamic response to hUII in man in vivo. Methods: Four healthy male volunteers took part in pilot studies and 11 in definitive studies. Forearm blood flow (FBF) was measured in response to 21 intra-arterial infusion of authentic, biologically active hUII (incremental rates of 0.001-300 pmol min ) and saline placebo using venous occlusion plethysmography. Blood pressure, heart rate, cardiac output and hUII plasma concentrations were also measured. Forearm studies were repeated in five subjects with inhibition of endothelial mediators using aspirin and a ''nitric oxide clamp''. Dorsal hand vein pmol min ) significantly increased plasma hUII concentrations from baseline (1263 pmol l ) to 106615 and 307698 pmol l , respectively. Despite high circulating hUII concentrations, no change was seen in systemic hemodynamics and ECGs were unchanged. Human UII had no effect on hand vein diameter (n56). Conclusions: In contrast to our hypothesised role of hUII, we found no vasoactive responses to hUII in vivo, consistent with recent in vitro studies in human blood vessels, but in contrast to non-human primate studies in vivo. Our data do not support a key role for hUII in the regulation of vascular tone and resting blood pressure in man. However, studies with hUII receptor antagonists are also needed before firm conclusions can be drawn.
Introduction
potent arterial vasoconstrictor yet discovered and has a sustained effect in blood vessels from a variety of species Human urotensin II (hUII) is a recently discovered [2, 4, 5] . vasoactive peptide hormone that acts as a high affinity
Human UII was first isolated in man from subgroups of ligand for rat G-protein receptor 14 (GPR14) [1] [2] [3] and the motor neurones in the spinal cord [1] . Outside the CNS, more recently discovered human receptor [3] . It is the most the kidney has the highest expression of prepro hUII mRNA and, therefore, appears the most likely source of circulating hUII [3] . Its receptor distribution has been hUII functions as an endocrine hormone. In vitro animal solved in either saline (0.9% Baxter Healthcare Ltd., ® data and studies in rats and non-human primates in vivo, Norfolk, UK) or Gelofusine (Braun Healthcare Ltd., indicate that hUII is a potent vasoconstrictor and influences Sheffield, UK). The drugs used were: hUII (Peptide cardiac function [2, 4] . However, conflicting results have Institute, Osaka, Japan, and SmithKline Beecham, PA, been obtained from human blood vessels in vitro [4] [5] [6] .
USA), angiotensin II (ANGII; Clinalfa, Laufelfingen, Although some studies suggest that hUII is 28-to 50-fold Switzerland), norepinephrine (NE; Abbott Laboratories, more potent than endothelin-1 (ET-1) [2, 4] , others show Kent, UK), sodium nitroprusside (SNP; David Bull Lab-G hUII to be a vasodilator [6] . In addition, there is some oratories, Warwick, UK) and L-N -monomethylarginine variability in response to hUII amongst species [7] , (L-NMMA; Clinalfa). depending on vessel location and type, and between
We confirmed the authentic nature of the hUII from both individual preparations. This is highlighted by some of the sources by high performance liquid chromatography and in vitro studies having responding and non-responding microsequencing (in the laboratory of Drs. S.A. Douglas vessels [5] . Interestingly, in the rat, the activity of hUII is and E.H. Ohlstein, SmithKline Beecham). We also conmost marked in the region of the proximal aorta, decreasfirmed the biological activity of the hUII peptides by ing rapidly further down the arterial tree [4] . Venoconstric- showing the anticipated responses, and potency, in the rat tion has been found only in some studies in vessels from proximal aorta (data not shown). non-human primates and humans and, in contrast to the effects of ET-1 and norepinephrine, where present, hUII is 2.3. Forearm blood flow less potent in veins than arteries [2, 4] .
To date, there have been no in vivo physiological studies Studies were performed with subjects resting supine, in of the actions of hUII in man. On the basis of animal in a quiet clinical laboratory, maintained at a constant temvivo and the positive human in vitro studies, we hypothperature of 22-248C. The brachial artery of the nonesised that hUII would cause arteriolar vasoconstriction in dominant arm was cannulated with a 27-gauge steel needle the human forearm, but have little or no effect in veins. We (Cooper's Needle Works) under local anesthesia (1% also anticipated that systemic dosing would raise peripherlignocaine; Astra Pharmaceuticals Ltd., Hertfordshire, al resistance and, hence, blood pressure. Our aim was to UK). This was connected to a constant rate infusion pump undertake the first human in vivo study with hUII, (IVAC) via a 16-gauge epidural catheter (Portex, UK).
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addressing local responses in human arterial vessels and Saline was infused at 1 ml min for a period of 30 min dorsal hand veins. Subsequently, we explored the effect of before drug infusion protocols were started to ensure a higher doses on systemic haemodynamics and plasma hUII stable baseline. The total infusion rate was kept constant at 21 concentrations. 1 ml min . Throughout the study FBF was measured simultaneously in both arms by venous occlusion plethysmography [8, 9] , as previously described [10] . FBF 2. Methods was measured over a 3 min period every 6 min, and the last five recordings of FBF were averaged to determine These studies were conducted with the approval of the flow in each arm. local research ethics committee and the written informed consent of each subject. The investigation conforms to the 2.4. Hand vein studies principles of the Declaration of Helsinki.
Studies were performed with the subject resting semi-2.1. Subjects recumbent in a quiet clinical laboratory maintained at a constant temperature between 24 and 268C. Studies were Fifteen healthy men, mean age 3764 years (range 22- carried out in accordance with our previously described 53), were recruited from a bank of community volunteers methodology using a standard displacement technique held by the Clinical Research Centre at the Western [11, 12] . A 2 cm length of non-branching dorsal hand vein General Hospital in Edinburgh. Four subjects took part in was cannulated in the direction of flow. A tripod was pilot studies and 11 in the definitive vein and forearm placed 1.5 cm proximal to the cannulation site as described studies. Subjects were asked to fast from midnight before in more detail previously by Aellig [11] . Saline was 21 each study, and to abstain from caffeine containing drinks, infused at a rate of 0.25 ml min for 30 min to allow alcohol and smoking over the preceding 24 h. Subjects' baseline measurements of vein diameter to be made. The
mean height was 17663 cm (range 170-180) and mean total infusion rate was kept constant at 0.25 ml min weight was 8068 kg (range 63-92).
throughout the study.
Drugs 2.5. Hemodynamics
All drugs were freshly prepared aseptically and disBlood pressure (BP) was recorded over the brachial artery in the non-infused arm using a validated oscillometric sphygmomanometer (HEM 705CP, Omron, Japan) [13] . Cardiac index (CI) was assessed using a validated [14] transthoracic electrical bioimpedance technique (NCCOM3, BoMed, Irvine, CA, USA). Both BP and CI were recorded after each FBF recording was completed. Mean arterial pressure was defined as diastolic pressure plus 1 / 3 of the pulse pressure. Peripheral vascular resistance (PVR) was calculated as MAP divided by CI and expressed in arbitrary units. Throughout the study continuous electrocardiographic (ECG) monitoring was employed and a full 12-lead ECG recorded at baseline and at the end of the highest UII infusion rate on each study day.
Plasma urotensin II levels
Plasma hUII concentrations were determined by radioimmunoassay using rabbit anti-flounder UII antibody and hUII iodinated by the Iodogen method of Fraker and Before assay, plasma samples were subject to reversethe two curves confirms the specificity of the assay for hUII and its phase chromatographic purification using Sep-Pak C18 suitability for plasma hUII measurements.
cartridges (Millipore, UK) with acetonitrile solvent. The assay protocol was based on that previously described for flounder UII [16] . Briefly, sample extract was incubated received a 30 min infusion of saline and then either hUII 125 with antibody (38,400 dilution) and I hUII at 48C for 24 (Peptide Institute) or saline in a single-blind, randomised 21 h. Following this, the complexes formed were precipitated manner. Four subjects received 30 and 100 pmol min 21 by the addition of bovine n-globulin (Sigma) and polyhUII, and six subjects 100 and 300 pmol min hUII. Each ethylene glycol (Sigma), and the bound fraction was rate was maintained for a total of 20 min and FBF counted for 10 min in a gamma counter (1275 minigamma, recorded at 3, 9 and 15 min. After the final FBF recording Wallac, Finland). A typical standard curve for the hUII during saline baseline infusions and each dose increment, radio-immunoassay is shown in Fig. 1 . Also shown is the systemic hemodynamic measurements were made (heart parallelism of serial dilutions of human plasma extract rate, BP and CI) and 10 ml of venous blood was collected with the standard curve established for synthetic hUII, for determination of plasma hUII concentration. In addiconfirming the specificity of the assay and its suitability for tion, FBF studies were repeated in some of the same measurement of plasma hUII. Recovery of hUII in plasma subjects. First, we used an alternative batch of hUII extracts was 63% and intra-and inter-assay coefficients of (SmithKline Beecham; dose range 0.1, 1, 10, 30 pmol 21 variation in our laboratory were 7.6 and 13.3%, respectivemin : six subjects). Second, we used an alternative hand vein followed by either L-NMMA (100 nmol min ) or saline in a single-blind, randomised manner for 5 min. 21 hUII was then co-infused at 3, 30 and 300 pmol min , each rate for 20 min. Saline was then infused for 10 min, 21 followed by ANGII (25 ng min ) for 3 min then saline 21 for a further 10 min and finally NE (8 ng min ) for 3 min to assess the integrity of the vein. Hand vein diameter was measured every 5 min after a 10 min baseline saline 21 infusion. The total infusion rate was kept at 0.25 ml min .
Statistical analysis
All results are expressed as mean6S.E.M. Data for FBF have been expressed as percent change from baseline of the FBF ratio (derived from infused arm value divided by non-infused arm value). Repeated measures ANOVA was used to identify differences in FBF response between hUII and saline, hUII concentrations during placebo and drug infusion and in the vein studies between presence and absence of hUII and L-NMMA co-infusion. For single 
Results
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ml 100 ml tissue min for Fig. 2B . There was no All subjects were symptom free throughout each study. significant change in FBF ratio during infusion of saline or Baseline FBF, heart rate, CI, BP, plasma hUII concenhUII in either of the dose ranging studies ( Fig. 2A and B ). trations and vein diameter were similar on the different There was no significant change in systemic hemodystudy days and there was no significant difference in the namics during infusion of hUII at any dose (Table 1A and basal FBF between the infused and non-infused arms. B). However, there was a substantial and significant Neither continuous single-lead ECG monitoring, nor the increase in circulating plasma hUII concentrations during full 12-lead ECGs, revealed any changes during the three hUII infusion (Fig. 3A and B) . Studies with hUII diluted in ® studies. Gelofusine rather than saline, and UII from an alternative supplier (SmithKline Beecham), similarly did not change 3.1. Pilot studies FBF or systemic hemodynamics (data not shown).
There was no significant change in FBF in either arm, or 3.3. Study 2 systemic hemodynamics, during infusion of saline or hUII (data not shown).
Baseline values for non-infused and infused FBF were 21 21 3.160.3 and 3.260.5 ml 100 ml tissue min , respec-3. (Fig. 4) . Co-infuwere as follows: 3.560.9 and 4.562 ml 100 ml tissue 21 21 min , respectively, for Fig. 2A and 2 .960.4 and 2.960.7 sion of SNP (mean dose 0.6 nmol min , range 0.3 to 1.0) returned the FBF ratio to baseline (160.1 at baseline and SNP (FBF ratio, P50.3). Human UII infusion did not compared with 0.860.1, P50.7 Student's t-test). There significantly alter heart rate, systolic or diastolic blood was no significant change in the FBF ratio, or FBF in pressure (P50.8, P50.8 and P50.3, respectively, either arm, during co-infusion of hUII following L-NMMA ANOVA).
Study 3
Increasing doses of hUII had no significant effect on hand vein diameter compared with baseline (P50.9, ANOVA) ( Table 2) . During co-infusion of hUII and L-NMMA, there was also no significant change in hand vein diameter (P50.8, ANOVA). In contrast, ANGII and NE both induced a substantial venoconstriction (see Table 2 ). The response to ANGII and NE was slightly higher during L-NMMA co-administration, but these differences from the response with L-NMMA were not significant (P50.8 and P50.2, respectively, Student's t-test). min UII infusion. *P,0.05, **P,0.01, ***P,0.001, Student's t-test baseline, Student's t-test. ANOVA for UII response was not significant, compared to baseline saline infusion (n56).
P50.3 (n55). 
Discussion
fold increase in plasma concentrations of ANGII in the non-infused arm caused mean arterial pressure to rise by The principal finding in these human in vivo studies is |15 mmHg [23] , whereas 30-fold increases in plasma hUII that infusion of hUII has no effect on arterial or venous had no effect. tone, or on systemic hemodynamics. In addition, combined
In any negative study it is important to consider the inhibition of NO and prostanoid production did not reveal possibility that a real effect on arteriolar tone was missed. any vasoactive effects of hUII in the forearm arteries or This is particularly important given the variability in the dorsal hand veins. We established the authentic nature of responses of isolated human vessels to hUII [4, 6, 7, 20] . the hUII by microsequencing and by showing that it was This is unlikely to be the case because there was no pharmacologically active in vitro. Furthermore, substantial suggestion of groups of responders and non-responders and consistent increases in plasma concentrations of hUII from the 15 subjects who received hUII over a wide range confirmed its delivery to the local and systemic circulation.
of doses. In addition, brachial infusion studies are an In isolated human arteries in vitro, Maguire et al. [4] extremely powerful tool for detecting vasoactive redemonstrated that hUII receptors are present in vascular sponses, usually requiring no more than six subjects to smooth muscle layers. In addition, they showed a positive have a high degree of confidence in showing statistically response to hUII where the potency of hUII in coronary, significant effects [9] . mammary and radial arteries was 50-fold greater than Previously, Gibson found that fish urotensin II caused ET-1. However, there were differences in the characterisendothelium dependent vasodilatation at low dose, prior to tics of the responses. The maximal responses to ET-1 were vasoconstriction, in rat aortic tissue [24] . This raised the consistently greater than those to hUII, and 30% of the possibility that hUII may induce activation of NOS and arteries failed to respond to hUII, whereas all responded to subsequent release of NO. To date, only one in vitro study ET-1. Recently, Hillier et al. [20] examined a wide range has studied the influence of NOS on responses to hUII [5] , of human arteries and veins of differing calibre in vitro, using L-N-nitro-arginine methylester (L-NAME) to inhibit and found no effect of hUII. The reason for this is not yet NOS in isolated pulmonary vessels [5] . L-NAME increased clear. Ames et al. performed a detailed in vivo study of the maximal responses but not potency of hUII in rat main systemic hemodynamic response to hUII in non-human pulmonary artery. L-NAME also enhanced maximal reprimates [2] . At lower systemic doses of hUII, Ames sponses to hUII in human pulmonary arteries, though only observed positive inotropism, whereas at higher doses hUII three of 10 vessels responded to hUII, and then only with induced ischaemic myocardial dysfunction and extreme very variable contractions. In the current studies, NO and rises in peripheral resistance. On the basis of early human prostanoid production were inhibited, using standard techin vitro and the in vivo cynomolgus monkey data, we niques. Even so, we were unable to unmask vasoconstrichypothesised that hUII would cause constriction of resisttion to hUII in either human resistance or capacitance ance vessels of the human forearm and raise blood vessels in vivo.
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pressure. Based on a FBF of 50 ml min and an infusion The lack of response of resistance vessels in vivo may 21 rate of 300 pmol min , the estimated local plasma be due to low receptor density or poor coupling to signal concentration of hUII in the infused arm in our study transduction mechanisms at this site, perhaps as part of 21 would be 6 nmol l , similar to those causing vasoconinter-species variation. The proximal aorta seems to be striction in human in vitro studies [4] . Nevertheless, we most sensitive to hUII and it is possible that subtle effects 21 found no effect of hUII at 300 pmol min for 20 min in on large arteries are caused by hUII but not detected using either the brachial artery or dorsal hand vein. This conroutine hemodynamic assessment. The in vivo effects of trasts markedly with the local vascular responses in hUII on human large arteries merits further investigation. humans to other paracrine and endocrine mediators, such A possible alternative explanation for the lack of effects of as ET-1 and ANGII, both of which cause |40% reduction hUII is high receptor occupancy. Studies with hUII 21 in FBF at only 5 pmol min [21, 22] , and suggests that antagonists in vivo can address this issue, and should allow hUII does not play an important role in regulating the physiological role of hUII in man to be more clearly peripheral vascular tone.
defined. In conclusion, we have found no evidence of local Indeed, during intra-arterial infusion of ANGII, a 10-or systemic hemodynamic effects of hUII in vivo despite
